Abstract
Background and aims: A substantial proportion of patients with adenomatous polyposis have no germline pathogenic variant in APC . The aim of this study was to determine the prevalence of APC mosaicism in these patients with unexplained polyposis and to draft guidelines for APC mosaicism testing and surveillance. Methods: APC mosaicism was analyzed by targeted Next-Generation sequencing in 542 patients with a broad spectrum of polyposis phenotypes. Results: The rate of APC mosaicism was 9.4%. This rate was 14.3% (46/322) in patients who meet the scope of national hereditary polyposis testing guidelines (≥10 adenomas before the age of 60 or with ≥20 adenomas before the age of 70). In patients who do not meet the scope of national guidelines, the detection rate was 2.3% (5/219). In patients with ≥20 adenomas before the age of 60, or ≥30 adenomas before the age of 70 the detection rate was ≥10%. Of 34 mosaic patients who underwent an esophagogastroduodenoscopy, 26% were diagnosed with gastroduodenal polyps. In one patient, the mosaic variant was detected in semen, but none of the children tested in this cohort inherited the mosaic variant. Conclusion: We recommend APC mosaicism testing at least in patients negative for germline pathogenic variants with (1) ≥20 adenomas before the age of 60 or (2) ≥30 adenomas before the age of 70. Regular colonoscopy and at least one gastroduodenoscopy should be offered to APC mosaics, with frequency of follow-up based on findings. Offering germline testing for offspring should be considered.

This publication has 21 references indexed in Scilit: